Kelly Shi
Stock Analyst at Jefferies
(1.10)
# 3,419
Out of 4,814 analysts
28
Total ratings
30.77%
Success rate
-11.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelly Shi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Initiates: Buy | $15 | $5.74 | +161.55% | 1 | Apr 10, 2025 | |
| OPT Opthea | Downgrades: Underperform | $1 | $3.41 | -70.67% | 1 | Mar 25, 2025 | |
| TIL Instil Bio | Upgrades: Buy | $11 → $52 | $15.46 | +236.46% | 2 | Jan 7, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Buy | $18 → $14 | $3.78 | +270.37% | 2 | Dec 16, 2024 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $13 → $19 | $12.25 | +55.10% | 2 | Sep 11, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $174 → $196 | $160.53 | +22.10% | 2 | Aug 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | $21 | $2.23 | +843.82% | 1 | Aug 13, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $37 | $11.51 | +221.46% | 1 | Jun 28, 2024 | |
| PROK ProKidney | Maintains: Buy | $15 → $6 | $0.71 | +744.95% | 2 | Jun 10, 2024 | |
| PTCT PTC Therapeutics | Maintains: Buy | $35 → $46 | $47.45 | -3.06% | 3 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $81 | $58.22 | +39.13% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $18.15 | +92.84% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.11 | +3,143.24% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $37.90 | -57.78% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $26.00 | +53.85% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.55 | +339.56% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.48 | +222.58% | 1 | Aug 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.53 | +5,035.03% | 1 | Mar 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $52 | $13.74 | +278.46% | 1 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.77 | +3,406.49% | 1 | Apr 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.53 | +2,056.86% | 1 | Mar 8, 2021 |
Verastem
Apr 10, 2025
Initiates: Buy
Price Target: $15
Current: $5.74
Upside: +161.55%
Opthea
Mar 25, 2025
Downgrades: Underperform
Price Target: $1
Current: $3.41
Upside: -70.67%
Instil Bio
Jan 7, 2025
Upgrades: Buy
Price Target: $11 → $52
Current: $15.46
Upside: +236.46%
Foghorn Therapeutics
Dec 16, 2024
Maintains: Buy
Price Target: $18 → $14
Current: $3.78
Upside: +270.37%
Centessa Pharmaceuticals
Sep 11, 2024
Maintains: Buy
Price Target: $13 → $19
Current: $12.25
Upside: +55.10%
Ascendis Pharma
Aug 13, 2024
Maintains: Buy
Price Target: $174 → $196
Current: $160.53
Upside: +22.10%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: $21
Current: $2.23
Upside: +843.82%
Syndax Pharmaceuticals
Jun 28, 2024
Initiates: Buy
Price Target: $37
Current: $11.51
Upside: +221.46%
ProKidney
Jun 10, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.71
Upside: +744.95%
PTC Therapeutics
May 20, 2024
Maintains: Buy
Price Target: $35 → $46
Current: $47.45
Upside: -3.06%
Feb 23, 2024
Initiates: Buy
Price Target: $81
Current: $58.22
Upside: +39.13%
Feb 20, 2024
Initiates: Buy
Price Target: $35
Current: $18.15
Upside: +92.84%
Feb 5, 2024
Initiates: Buy
Price Target: $36
Current: $1.11
Upside: +3,143.24%
Nov 11, 2022
Initiates: Buy
Price Target: $16
Current: $37.90
Upside: -57.78%
Aug 15, 2022
Initiates: Buy
Price Target: $40
Current: $26.00
Upside: +53.85%
Aug 15, 2022
Initiates: Buy
Price Target: $20
Current: $4.55
Upside: +339.56%
Aug 3, 2022
Initiates: Buy
Price Target: $8
Current: $2.48
Upside: +222.58%
Mar 4, 2022
Initiates: Buy
Price Target: $27
Current: $0.53
Upside: +5,035.03%
Aug 3, 2021
Initiates: Buy
Price Target: $52
Current: $13.74
Upside: +278.46%
Apr 13, 2021
Initiates: Buy
Price Target: $27
Current: $0.77
Upside: +3,406.49%
Mar 8, 2021
Initiates: Buy
Price Target: $33
Current: $1.53
Upside: +2,056.86%